| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/04/2006 | WO2005118777A3 Novel saccharothrix strain and antibiotics derived therefrom, i.e. mutactimycins and aldgamycins |
| 05/04/2006 | WO2005112965A3 Botanical anti-inflammatory compositions and methods |
| 05/04/2006 | WO2005112546A3 Mucinous glycoprotein (muc-1) vaccine |
| 05/04/2006 | WO2005106492A3 Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3) |
| 05/04/2006 | WO2004004708A9 A pharmaceutical composition useful for treating chronic myeloid leukemia |
| 05/04/2006 | US20060094784 Tgf-alpha expression inhibitors |
| 05/04/2006 | US20060094766 Epothilone derivatives for the treatment of multiple myeloma |
| 05/04/2006 | US20060094746 poly(ADP-ribose) polymerase (PARP) inhibitors such as 9-hydroxythieno[2,3-c]isoquin-5(4H)-one, used for treating tumor diseases, leukaemia, sarcoma, tissue damage due to ischemia and reperfusion, inflammatory disease, retinal ischemia or brain trauma |
| 05/04/2006 | US20060094735 Compounds for cell proliferation, anticancer agents, kinesin inbiitors |
| 05/04/2006 | US20060094729 metastatic or non-metastatic prostate cancer; for inducing apoptosis |
| 05/04/2006 | US20060094727 Inhibitors of macrophase migration inhibitory factor and methods for identifying the same |
| 05/04/2006 | US20060094725 N-heterocyclic derivatives as NOS inhibitors |
| 05/04/2006 | US20060094711 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| 05/04/2006 | US20060094694 Heterocyclic compounds and thrombopoietin receptor activators |
| 05/04/2006 | US20060094665 Pharmaceutical angiostatic dipeptide compositions and methods of use thereof |
| 05/04/2006 | US20060094660 Inhibitor of the shh signalling patway and a testosterone supressing agent for the treatment of cancer |
| 05/04/2006 | US20060094069 Tumour marker proteins and uses thereof |
| 05/04/2006 | US20060094043 Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof |
| 05/04/2006 | US20060094012 Polymorphisms for predicting disease and treatment outcome |
| 05/04/2006 | US20060094007 Method of identifying pancreatic ductal carcinoma-specific gene using pancreatic ductal cells, method of testing for pdc using said genes, and method of screening pharmaceutical candidate compounds for treating or preventing pdc |
| 05/04/2006 | US20060093690 Novel therapeutic use of polypodium extracts |
| 05/04/2006 | US20060093662 Liposomal camptothecins and uses thereof |
| 05/04/2006 | US20060093618 Agaricus blazei murill extract capable for preventing cancer induction or metastasis |
| 05/04/2006 | US20060093612 Use of heat shock proteins to enhance efficacy of antibody therapeutics |
| 05/04/2006 | US20060093611 from mammalian chondrocyte progenitor cells expressing mechanosensitive TWIK-related potassium (TREK) ion channels; biocompatability, in vitro |
| 05/04/2006 | US20060093600 Antibodies to CD40 |
| 05/04/2006 | US20060093598 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 05/04/2006 | US20060093576 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 05/04/2006 | US20060093575 Oxaliplatin anti-resistance agent |
| 05/04/2006 | DE102004052533A1 Particles for use in diagnosis and therapy, especially for binding therapeutic agent for treating e.g. tumors and bacterial, rheumatic, neurologic and thrombotic diseases, have nanocrystalline magnetic core and envelope enclosing core |
| 05/04/2006 | CA2592351A1 Transcriptional inhibitor for human k-ras gene |
| 05/04/2006 | CA2586738A1 (2-carboxamido)(3-amino) thiophene compounds |
| 05/04/2006 | CA2585638A1 Aminopyridine derivatives having aurora a selective inhibitory action |
| 05/04/2006 | CA2585268A1 Methods for lowering hif-1 mediated gene expression |
| 05/04/2006 | CA2585196A1 Anti-glypican 3 antibody having modified sugar chain |
| 05/04/2006 | CA2584752A1 Triazoles useful as inhibitors of protein kinases |
| 05/04/2006 | CA2583677A1 Tnf-like weak inducer of apoptosis (tweak) receptor binding domain |
| 05/04/2006 | CA2582247A1 3-arylamino pyridine derivatives |
| 05/03/2006 | EP1652936A2 cDNA for human methylenetetrahydrofolate reductase |
| 05/03/2006 | EP1652931A2 Recombinant adenoviruses, preparation and uses thereof for the treatment and/or prevention ofs cancers |
| 05/03/2006 | EP1652917A1 Rna capable of inhibiting expression of klf5 gene |
| 05/03/2006 | EP1652854A1 Indolopyrrolocabazole derivative and antitumor agent |
| 05/03/2006 | EP1652853A1 Crystalline 6-n-pyridylmethylaminoindolocarbazole compounds |
| 05/03/2006 | EP1652849A1 Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents |
| 05/03/2006 | EP1652847A1 Quinoline and quinazoline derivatives for the treatment of tumors |
| 05/03/2006 | EP1652842A1 Indazole derivatives |
| 05/03/2006 | EP1652539A1 Method of manufacturing a stent comprising an anti-angiogenic composition |
| 05/03/2006 | EP1652530A1 Drug promoting ceramide transport, base sequence for producing the drug, method of measuring activity of promoting ceramide release and method of measuring activity of promoting intermembrane ceramide transfer |
| 05/03/2006 | EP1652529A2 Antiproliferative and antiviral proteins and peptides |
| 05/03/2006 | EP1652528A1 Activated carbon infusion solution, preparation method therefor and use thereof for the manufacture of drug for treating cancer |
| 05/03/2006 | EP1652519A1 Seleniferous composition for producing antioxidase in vivo |
| 05/03/2006 | EP1652515A1 Process for producing drug ultramicroparticle and apparatus therefor |
| 05/03/2006 | EP1651956A2 Melks as modifiers of the rac pathway and methods of use |
| 05/03/2006 | EP1651762A2 Small interfering rna specific to sub-units $g(a), $g(a)' and $g(b) of the kinase protein ck2, and the applications of the same |
| 05/03/2006 | EP1651684A1 Etherified carbamate functional copolymers of isobutylene type monomers, and their use in curable compositions |
| 05/03/2006 | EP1651652A1 Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders |
| 05/03/2006 | EP1651633A1 Substituted lactams and their use as anti-cancer agents |
| 05/03/2006 | EP1651626A1 Urea derivatives and their use as tyrosinkinase inhibitors |
| 05/03/2006 | EP1651612A1 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| 05/03/2006 | EP1651611A2 Benzimidazole c-2 heterocycles as kinase inhibitors |
| 05/03/2006 | EP1651602A2 Aryl heteroaromatic products, compositions comprising the same and use thereof |
| 05/03/2006 | EP1651600A2 Novel n -substituted indolyl-3-glyoxylic acid amides, use thereof as a medicament, and method for the production thereof |
| 05/03/2006 | EP1651599A1 Tyrosine kinase inhibitors |
| 05/03/2006 | EP1651287A2 Injectable composite for the magnetocytolysis of bone metastatic cells |
| 05/03/2006 | EP1651267A1 Methods of therapy for chronic lymphocytic leukemia |
| 05/03/2006 | EP1651257A1 Targeted therapeutic vaccine against p-glycoprotein 170 for inhibiting multi-drug resistance in the treatment of cancers |
| 05/03/2006 | EP1651256A1 Human prostate cell lines in cancer treatment |
| 05/03/2006 | EP1651247A1 Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin |
| 05/03/2006 | EP1651238A1 Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss |
| 05/03/2006 | EP1651227A1 Combination therapy |
| 05/03/2006 | EP1651214A2 Benzimidazole derivatives as mek inhibitors |
| 05/03/2006 | EP1651211A2 Combination of drugs for the treatment of neoplasms |
| 05/03/2006 | EP1651198A2 Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| 05/03/2006 | EP1576150A4 Methods and compositions for increasing the efficacy of biologically-active ingredients |
| 05/03/2006 | EP1560828B1 Imidazoquinoline derivatives as adenosine a3 receptor ligands |
| 05/03/2006 | EP1546205A4 Methods for regulating cancer |
| 05/03/2006 | EP1528923B1 N-((3-oxo-2,3-dihydro-1h-isoindol-1-yl)acetyl)guanidine derivatives as nhe1-inhibitors for the treatment of infarction and angina pectoris |
| 05/03/2006 | EP1515955A4 Chemical process |
| 05/03/2006 | EP1513836B1 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof |
| 05/03/2006 | EP1505930A4 Drug-delivery endovascular stent and method for treating restenosis |
| 05/03/2006 | EP1499606B1 3, 4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists |
| 05/03/2006 | EP1448986B1 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 05/03/2006 | EP1425046A4 Wild-type ras as a cancer therapeutic agent |
| 05/03/2006 | EP1381358B1 Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp |
| 05/03/2006 | EP1368006B1 Novel modified released formulation |
| 05/03/2006 | EP1351954B1 Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives |
| 05/03/2006 | EP1289923B1 Epithelial cell cancer drug |
| 05/03/2006 | EP1242400B1 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 05/03/2006 | EP1242060B1 Treatment of metastatic disease |
| 05/03/2006 | EP1232748B1 Use of substituted nitrobenzene derivatives for the treatment of diseases caused by bacteria, fungi and viruses |
| 05/03/2006 | EP1227805B1 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 05/03/2006 | EP1210065B1 Cationic liposome delivery of taxanes to angiogenic blood vessels |
| 05/03/2006 | EP1189611B1 Cancer therapy |
| 05/03/2006 | EP1104309B1 Co-lyophilized complex comprising a nucleic acid vector and a formulating agent |
| 05/03/2006 | EP1074542B1 Sulfonamide-containing indole compounds |
| 05/03/2006 | EP1003508B1 Antimutagenic agents |
| 05/03/2006 | EP0927217B1 Angiogenic inhibitory compounds |
| 05/03/2006 | EP0793500B1 Pharmaceutical compositions comprising nitric oxide-releasing polysaccharides |
| 05/03/2006 | EP0672042B1 Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof |
| 05/03/2006 | CN1768071A Lipid-regulating agent and use thereof |